Background: Early diagnosis is crucial for management of patients with suspected acute myocardial infarction (AMI). Among innovative and promising biomarkers, the recent interest raised on glycogen phosphorylase isoenzyme BB (GPBB) has prompted us to perform a meta-analysis of published studies. Materials and methods: A systematic electronic search was carried out on PubMed, Web of Science and Google Scholar, with no date restriction, to retrieve all articles that have investigated the early diagnostic performance of GPBB in patients with suspected AMI, and directly reported or allowed calculation of sensitivity and specifi city. A meta-analysis of the reported sensitivity and specifi city of each study and pooled area under the curve (AUC) was then performed by random eff ect approach. Heterogeneity was assessed by I-square statistics. Results: Eight studies were fi nally selected for analysis (941 subjects; 506 cases and 435 controls), with a high heterogeneity (I-squared, 86.3%). The resulting pooled estimates and 95% confi dence interval were 0.854 (0.801-0.891) for sensitivity, 0.767 (0.713-0.815) for specifi city, 0.826 (0.774-0.870) for negative predictive value, 0.802 (0.754-0.844) for positive predictive value, and 0.754 (0.602-0.907) for AUC. In those studies that have simultaneously assessed GPBB and a troponin immunoassay, the combination of these biomarkers did not signifi cantly improve the performance of troponin alone. Conclusion: GPBB does not meet the current requirements for an effi cient diagnosis of AMI when used as a stand-alone test, whereas its combination with troponin merits further investigation in larger trials.
Introduction
Acute myocardial infarction (AMI) is the most disabling and deadly disease in western countries, causing ~15% of all deaths in the United States, according to the recent statistics of the American Heart Association (1). An early diagnosis (i.e., within 3 to 6 hours from onset of the symptoms) and an effi cient risk stratifi cation are crucial for management of patients with suspected acute coronary syndrome, since eff ective myocardium salvage is only achieved when revascularization is established within 6 hours from onset of the symptoms.
An effi cient triage is also essential to face the constant overcrowding of emergency departments (EDs), which inherently causes inadequate quality of care and patient distress (2) . Beyond consolidated use of troponin testing, which is the biochemical gold standard in the diagnostic approach of patients with suspected AMI, there is spasmodic research on additional biomarkers that would enable fast and appropriate triage of patients in the ED, as well as in the coronary care unit (CCU) (3, 4) . Among innovative and promising biomarkers of Lippi G. et al. Meta-analysis of GPBB in myocardial infarction AMI, the development of commercial immunoassays has contributed to renew the interest on glycogen phosphorylase isoenzyme BB (GPBB).
GPBB is a fundamental enzyme in the regulation of carbohydrate metabolism by mobilization of glycogen. Three diff erent isoenzymes exist; glycogen phosphorylase isoenzyme MM (GPMM) is prevalently contained in human skeletal muscle, glycogen phosphorylase isoenzyme LL (GPLL) is contained in liver and all other tissues except heart, skeletal muscle, and brain, whereas GPBB is predominantly produced by brain and heart, wherein the 94 kD monomer is present in comparable tissue concentration (5) . A serum increase of GPBB should hence be highly specifi c for myocardial injury when damage to the brain and consequent perturbation of blood-brain barrier has been ruled out.
The very fi rst evidence of GPBB testing in patients with AMI was provided more than 25 years ago by Rabitzsch et al., who showed that this biomarker is rapidly released into the circulation in the early phase of AMI (6,7). These preliminary fi ndings paved the way to a series of further trials. In a recent article published in this journal, Cubranic et al. concluded that GPBB may contribute to early diagnosis of ischemic heart disease, with sensitivity of 0.97 and specifi city of 0.81 in patients with AMI admitted within 3 hours from onset of the symptoms (8) . These interesting results prompted us to perform a meta-analysis of published studies that have assessed the diagnostic performance of GPBB in patients with suspected AMI.
Materials and methods

Search methodology
We carried out a systematic electronic search on the three most accessed scientifi c databases (i.e., PubMed, Web of Science and Google Scholar) (9), with no date restriction, to retrieve all articles that have investigated the early diagnostic performance (i.e., within 6 hours from the onset of the symptoms) of GPBB in trials with a sample size of not less than 20 patients with suspected AMI. The following keywords were used: "myocardial infarction" or "ischaemic heart disease" "or "acute coronary syndrome", in combination with "glycogen phosphorylase isoenzyme BB" or "GPBB" or "GP-BB". The bibliographic references of the articles published in English, French, Spanish and Italian were reviewed for additional relevant studies. All the articles identifi ed according to these search criteria were systematically assessed for quality by two authors (GL and GC), according to the Quality Assessment of Diagnostic Accuracy Studies (QUA-DAS) checklist criteria (10) . Disagreements were resolved by a third opinion (CM). After careful reading of abstract and text, only articles directly reporting or allowing calculation on a 2×2 contingency table of sensitivity and specifi city according to accuracy data in combination with prevalence and sample size were deemed eligible for metaanalysis. When multiple time points were available, we limited the extraction to data of the earliest sampling (i.e., within 6 hours). Abstracts, review articles, and/or lecture presentations, as well as articles that were not fulfi lling the aforementioned criteria were discarded. The number of patients with a true-positive, false-positive, false-negative and true-negative test results of GPBB in patients with suspected AMI was extracted, along with information on assays used and cohort enrolled.
Statistical analysis
Heterogeneity was assessed by the chi-square based statistics and I-square test, wherein thresholds of 25%, 50% and 75% designate low, moderate, and high heterogeneity (11) . The cumulative estimates and 95% confi dence interval (95% CI) of sensitivity, specifi city, negative predictive value (NPV) and positive predictive value (PPV) were further calculated using a random eff ect model for Isquare values greater than 50%. The area under the receive operator characteristic (ROC) curve (AUC) values with 95% CI weighted for sample size were pooled according to Higgins et al. (11) . Statistical analysis was performed with MedCalc Version 12.3.0 (MedCalc Software, Mariakerke, Belgium).
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Results
The electronic search according to the above mentioned criteria identifi ed 45 citations of studies and abstracts after elimination of replicates among the three searchable databases. Thirty six studies were excluded after abstract and/or full text reading because GPBB was not assessed in the setting of AMI diagnostics. The remaining nine studies were carefully assessed for quality after revision of the full text, and one was excluded because it did not contain suffi cient information for calculating either the pooled AUC, or the pooled estimates of sensitivity and specifi city. Inter-rater reliability was excellent (k = 0.93; P < 0.001).
Overall, eight studies were fi nally selected for analysis, all containing complete data for calculating the pooled AUC, whereas only seven provided suf- fi cient information for calculating the cumulative sensitivity, specifi city, NPV and PPV (Table 1) (8, (12) (13) (14) (15) (16) (17) (18) . The eight studies (mean quality score, 10.3) totaled 941 subjects (506 AMI cases and 435 controls). The between-study variation was high and attributable to heterogeneity (chi-squared, 58.40; DF, 8; I-squared, 86.3%; P < 0.001). In 5 out of 8 studies (62%) the setting was the ED, whereas patients were directly admitted to the CCU in two studies, and to the intensive care unit in one trial. GPBB was assayed with the Diacordon® GPBB-ELI-SA test (Diagenics, Woburn, MA, USA) in six studies, whereas it was measured with Evidence® Cardiac Panel (RANDOX Laboratories Ltd., United Kingdom) and in-house developed immunoassay in the remainders. The diagnostic threshold of Lippi G. et al. Meta-analysis of GPBB in myocardial infarction GPBB was comparable across the studies, being comprised between 7 and 10 μg/L. The diagnostic performances of the eight studies as well as the pooled data are shown in Table 1 Figure 1 .
those of the current high-sensitive immunoassays, which are typically characterized by AUCs of ~0.96, sensitivity greater than 0.85, NPV greater than 0.99 and specifi city values comprised between 0.80 and 0.93 (19) . No one of the pooled estimates of GPBB outweighed or even approximated these excellent diagnostic performances. The lowest estimate of GPBB was obtained for specifi city, but this is not surprising inasmuch as the concentration of this biomarker is infl uenced by skeletal muscle injury, as clearly shown by Lippi et al. who reported a signifi cant post-exercise GPBB increase of ~40% after a 21-km run in trained athletes (20) . The assessment of the article of Figiel et al., which had been originally excluded from our meta-analysis due to the lack of a reference group which did not allow to gather information on specifi city and AUC, also revealed a poor sensitivity (i.e., 0.47) of GPBB in 20 patients with AMI, in whom the biomarker had been assessed < 3 hours from the onset of the symptoms (21) . It is noteworthy, however, the four studies that enrolled the patients within 1 to 3 hours from the onset of chest pain showed a much better sensitivity (0.96-1.0) than the remainders, and this is attributable to early release of GPBB due to burst in glycogenolysis and a concomitant increase in plasma membrane permeability that both occur immediately after myocardial ischemia (5).
In those studies that have simultaneously assessed GPBB and a troponin immunoassay (14, 16, 18) , their combination (either marker positive) did not signifi cantly improve the performance of troponin alone. For example, Meune et al. reported an AUC of 0.842 for troponin alone versus 0.854 for the combination (P = 0.728) (18) . Even more interestingly, in the study of Mion et al., the diagnostic effi cacy of troponin alone was even greater than that combining troponin and GPBB (83.3 versus 69.7%) (14) . We thereby conclude that GPBB does not met the current requirements for an effi cient diagnosis of AMI when used as a stand-alone test, whereas its combination with troponin merits further investigation in larger trials.
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Discussion
Only a few reliable studies have been published so far on the potential role of GPBB as a stand-alone test in the triage approach of patients with suspected ischaemic heart disease. Although the outcome of some of these was promising, showing excellent values of sensitivity and specifi city, the results of others were instead disappointing ( Table  1) . Regardless of the broad heterogeneity that we found across the studies included in this metaanalysis, our results clearly attest that the diagnostic performance of GPBB are much lower than
